Drug Trial Radar · NCT06833983
To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
Last checked: Nov 20, 2026Latest source record: Dec 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Mar 31, 2025
Primary completion
Nov 30, 2026
Study completion Nov 30, 2030
Sponsor
- Lead sponsor
- Gritgen Therapeutics Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Feb 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single-arm, open-label, multicenter study evaluating the efficacy and safety of GS1191-0445 injection as a single dose in Chinese subjects with hemophilia A. GS1191-0445 is an AAV8-based gene therapy vector designed to express B-domain deleted human factor VIII (FVIII) under the regulation of a human liver-specific promoter. Following a single intravenous administration, AAV8 targets hepatocytes and facilitates the specific expression and secretion of FVIII into the bloodstream.
Conditions
- Hemophilia A
Interventions
GS1191-0445 injectionDrug
A single intravenous administration of GS1191-0445 injection at a dose of 3E12 vg/kg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Bleeding Rate (ABR)Time frame: Weeks 3 to 52 after infusion
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Anhui Provincial Hospital
Hefei, Anhui, China · Not yet recruiting
Peking Union Medical College Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
First Hospital of Lanzhou University
Lanzhou, Gansu, China · Not yet recruiting
Nanfang Hospital Southern Medical University
Guangzhou, Guangdong, China · Not yet recruiting
North China University of Science and Technology Affiliated Hospital
Tangshan, Hebei, China · Not yet recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Not yet recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Not yet recruiting
Xiangya Hospital of Central South University
Changsha, Hunan, China · Not yet recruiting
Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School
Nanjing, Jiangsu, China · Not yet recruiting
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, China · Not yet recruiting
Central Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, China · Recruiting
Institute of Hematology & Blood Diseases Hospital Chinese Academy of Medical Sciences & Peking Union Medical College
Tianjin, Tianjin Municipality, China · Recruiting
The second Affiliated Hospital of Kunming Medical University
Kunming, Yunnan, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.